ω-3 tear film lipids correlate with clinical measures of dry eye

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 6, 2016, Pages 2472-2478

  Walter, Scott D ^a   Gronert, Karsten ^b   McClellan, Allison L ^c   Levitt, Roy C ^c,d   Sarantopoulos, Konstantinos D ^c,d   Galor, Anat ^a,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Dry eyes; Fatty acids; Nutrition; Prostaglandins; Tears

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; ARTIFICIAL TEAR; AUTACOID; DOCOSAHEXAENOIC ACID; FISH OIL; FLUORESCEIN; HEPOXILIN A; IBUPROFEN; ICOSAPENTAENOIC ACID; LIPOXIN A; NAPROXEN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; OXYGENASE; PROSTAGLANDIN E2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA SENSIBILITY; CORNEAL STAINING; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRY EYE; ETHNICITY; EYE PAIN; FEMALE; HUMAN; LACRIMAL FLUID; LIPID ANALYSIS; LIPID MEMBRANE; LIPIDOMICS; LIQUID CHROMATOGRAPHY; MALE; MEIBOMIAN GLAND DYSFUNCTION; OCULAR SURFACE DISEASE; OPHTHALMIC ESTHESIOMETER; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUPPLEMENTATION; TANDEM MASS SPECTROMETRY; TEAR BREAKUP TIME; TEAR FILM; TEAR FILM DYSFUNCTION; TEAR FLOW; TEAR OSMOLARITY; VASCULARIZATION; CORNEA; DRY EYE SYNDROMES; FOLLOW UP; INNERVATION; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PERCEPTIVE THRESHOLD; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CORNEA; CROSS-SECTIONAL STUDIES; DRY EYE SYNDROMES; FATTY ACIDS, OMEGA-3; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; RETROSPECTIVE STUDIES; SENSORY THRESHOLDS; TEARS;

EID: 84965034278     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-19131     Document Type: Article

References (49)

1. Galor A, Levitt RC, Felix ER, et al. Neuropathic ocular pain: an important yet underevaluated feature of dry eye. Eye (Lond). 2015; 29: 301-312.
2. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Work Shop (2007). Ocul Surf. 2007; 5: 93-107.
3. Pouyeh B, Viteri E, Feuer W, et al. Impact of ocular surface symptoms on quality of life in a United States Veterans Affairs population. Am J Ophthalmol. 2012; 153: 1061-1066.
4. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjogren's and non-Sjogren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002; 43: 2609-2614.
5. Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol. 2013; 32: 19-41.
6. Wei Y, Gadaria-Rathod N, Epstein S, et al. Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures. Invest Ophthalmol Vis Sci. 2013; 54: 8327-8336.
7. Yoon KC, Park CS, You IC, et al. Expression of CXCL9,-10,-11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci. 2010; 51: 643-650.
8. Shim J, Park C, Lee HS, et al. Change in prostaglandin expression levels and synthesizing activities in dry eye disease. Ophthalmology. 2012; 119: 2211-2219.
9. Srinivasan BD, Kulkarni PS. The role of arachidonic acid metabolites in the mediation of the polymorphonuclear leukocyte response following corneal injury. Invest Ophthalmol Vis Sci. 1980; 19: 1087-1093.
10. Serhan CN. Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007; 25: 101-137.
11. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010; 140: 871-882.
12. Serhan CN. Novel chemical mediators in the resolution of inflammation: Resolvins and protectins. Anesthesiol Clin. 2006; 24: 341-364.
13. Spite M, Claria J, Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 2014; 19: 21-36.
14. Cortina MS, He J, Li N, et al. Recovery of corneal sensitivity, calcitonin gene-related peptide-positive nerves, and increased wound healing induced by pigment epithelial-derived factor plus docosahexaenoic acid after experimental surgery. Arch Ophthalmol. 2012; 130: 76-83.
15. Cortina MS, Bazan HE. Docosahexaenoic acid, protectins and dry eye. Curr Opin Clin Nutr Metab Care. 2011; 14: 132-137.
16. de Paiva CS, Schwartz CE, Gjorstrup P, et al. Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye. Cornea. 2012; 31: 1299-1303.
17. Cortina MS, He J, Li N, et al. Neuroprotectin D1 synthesis and corneal nerve regeneration after experimental surgery and treatment with PEDF plus DHA. Invest Ophthalmol Vis Sci. 2010; 51: 804-810.
18. Dartt DA, Hodges RR, Li D, et al. Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation. J Immunol. 2011; 186: 4455-4466.
19. Esquenazi S, Bazan HE, Bui V, et al. Topical combination of NGF and DHA increases rabbit corneal nerve regeneration after photorefractive keratectomy. Invest Ophthalmol Vis Sci. 2005; 46: 3121-3127.
20. Li N, He J, Schwartz CE, et al. Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther. 2010; 26: 431-439.
21. Gronert K. Resolution, the grail for healthy ocular inflammation. Exp Eye Res. 2010; 91: 478-485.
22. Bazan NG, Molina MF, Gordon WC. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr. 2011; 31: 321-351.
23. Kenchegowda S, Bazan HE. Significance of lipid mediators in corneal injury and repair. J Lipid Res. 2010; 51: 879-891.
24. Miljanovic B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr. 2005; 82: 887-893.
25. Kangari H, Eftekhari MH, Sardari S, et al. Short-term consumption of oral omega-3 and dry eye syndrome. Ophthalmology. 2013; 120: 2191-2196.
26. Kawakita T, Kawabata F, Tsuji T, et al. Effects of dietary supplementation with fish oil on dry eye syndrome subjects: randomized controlled trial. Biomed Res. 2013; 34: 215-220.
27. Gao Y, Min KJ, Zhang YB, et al. Female-specific downregulation of tissue polymorphonuclear neutrophils drives impaired regulatory T cell and amplified effector T cell responses in autoimmune dry eye disease. J Immunol. 2015; 195: 3086-3099.
28. Leedom AJ, Sullivan AB, Dong B, et al. Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury. Am J Pathol. 2010; 176: 74-84.
29. Biteman B, Hassan IR, Walker E, et al. Interdependence of lipoxin A4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing. FASEB J. 2007; 21: 2257-2266.
30. Wang SB, Hu KM, Seamon KJ, et al. Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea. FASEB J. 2012; 26: 1506-1516.
31. Liclican EL, Nguyen V, Sullivan AB, et al. Selective activation of the prostaglandin E2 circuit in chronic injury-induced pathologic angiogenesis. Invest Ophthalmol Vis Sci. 2010; 51: 6311-6320.
32. Cortina MS, He J, Russ T, et al. Neuroprotectin D1 restores corneal nerve integrity and function after damage from experimental surgery. Invest Ophthalmol Vis Sci. 2013; 54: 4109-4116.
33. Begley CG, Caffery B, Chalmers RL, et al. Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye. Cornea. 2002; 21: 664-670.
34. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000; 118: 615-621.
35. Foulks GN, Bron AJ. Meibomian gland dysfunction: A clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003; 1: 107-126.
36. Belmonte C, Acosta MC, Schmelz M, et al. Measurement of corneal sensitivity to mechanical and chemical stimulation with a CO2 esthesiometer. Invest Ophthalmol Vis Sci. 1999; 40: 513-519.
37. Situ P, Simpson TL, Fonn D. Eccentric variation of corneal sensitivity to pneumatic stimulation at different temperatures and with CO2. Exp Eye Res. 2007; 85: 400-405.
38. von Moltke J, Trinidad NJ, Moayeri M, et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature. 2012; 490: 107-111.
39. Prüss H, Rosche B, Sullivan AB, et al. Proresolution lipid mediators in multiple sclerosis-differential, disease severitydependent synthesis-a clinical pilot trial. PLoS One. 2013; 8: e55859.
40. Kalish BT, Le HD, Fitzgerald JM, et al. Intravenous fish oil lipid emulsion promotes a shift toward anti-inflammatory proresolving lipid mediators. Am J Physiol Gastrointest Liver Physiol. 2013; 305: G818-G828.
41. Sapieha P, Stahl A, Chen J, et al. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids. Sci Transl Med. 2011; 3: 69ra12.
42. Harauma A, Saito J, Watanabe Y, et al. Potential for daily supplementation of n-3 fatty acids to reverse symptoms of dry eye in mice. Prostaglandins Leukot Essent Fatty Acids. 2014; 90: 207-213.
43. Chen D, Wei Y, Li X, et al. sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised. Exp Eye Res. 2009; 88: 880-888.
44. Mieyal PA, Dunn MW, Schwartzman ML. Detection of endogenous 12-hydroxyeicosatrienoic acid in human tear film. Invest Ophthalmol Vis Sci. 2001; 42: 328-332.
45. Calder PC, Dangour AD, Diekman C, et al. Essential fats for future health. Proceedings of the 9th Unilever Nutrition Symposium, 26-27 May 2010. Eur J Clin Nutr. 2010; 64(suppl 4): S1-S13.
46. Elmadfa I, Kornsteiner M. Dietary fat intake-a global perspective. Ann Nutr Metab. 2009; 54(suppl 1): 8-14.
47. Gronert K, Maheshwari N, Khan N, et al. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem. 2005; 280: 15267-15278.
48. Mukherjee PK, Marcheselli VL, Serhan CN, et al. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A. 2004; 101: 8491-8496.
49. Pace-Asciak CR. Formation of hepoxilin A4, B4 and the corresponding trioxi lins from 12(S)-hydroperoxy-5, 8, 10, 14, 17-icosapentaenoic acid. Prostaglandins Leukot Med. 1986; 22: 1-9.